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ABSTRACT	Thyroid	eye	disease	(TED)	is	a	potentially	sight-threatening	and	cosmetically	disfiguring	condition	arising	in	25-50%	of	patients	with	Graves'	hyperthyroidism.	CIRTED	is	the	first	study	to	evaluate	the	long-term	role	of	radiotherapy	and	prolonged	immunosuppression	with	azathioprine	in	treating	TED,	one	aim	of	which	was	to	validate	the	use	of	the	English	version	of	GO-QOL	in	an	UK	population	with	TED.	In	a	three	stage	design	over	a	48	week	period,	the	GO-QOL	was	tested	and	compared	to	a	general	measure	of	quality	of	life	(WHOQOL-Bref).	In	stage	1	utilising	a	standard	14	day	test-retest	design	both	GO-QOL	subscales	achieved	Cronbach’s	alphas	demonstrating	excellent	validity	and	internal	reliability	(Visual	Function	0.929	and	0.931;	Appearance	0.888	and	0.906).	In	stage	2,	Repeated	Measures	ANOVA	demonstrated	longitudinal	validity,	with	both	subscales	of	the	GO-QOL	showing	significant	change	over	time	(Visual	Function,	p<.001;	Appearance,	p<.002).	In	stage	3	the	GO-QOL	showed	discriminant	validity	at	the	week	48	time	point,	with	the	visual	function	subscale	being	able	to	detect	changes	in	groups	identified	by	clinicians	(using	BCCOM	ratings	of	improvement	or	deterioration),	while	both	subscales	could	detect	group	differences	when	based	on	participants’	subjective	ratings	of	TED	noticeability	and	severity.	The	results	of	this	project	provide	support	for	the	English	translation	of	the	GO-QOL	as	an	outcome	measure	for	patients	with	moderately	severe	active	Graves'	orbitopathy/TED.		





	 	Currently	the	management	of	GO/TED	is	considered	suboptimal,	and	available	treatments	do	not	specifically	target	the	underlying	pathogenic	process	(Bartalena	et	al,	2016).	The	Combined	Immunosuppression	and	Radiotherapy	in	Thyroid	Eye	Disease	(CIRTED)	trial	was	designed	to	assess	the	effect	of	using	radiotherapy	and	the	immunosuppressive	drug	azathioprine	in	combination	with	standard	prednisolone	treatment	(Rajendram	et	al,	2008).	CIRTED	is	the	first	study	to	evaluate	the	long-term	role	of	radiotherapy	and	prolonged	immunosuppression	with	azathioprine	in	treating	GO/TED.			It	is	well	established	that	TED	can	have	a	major	impact	on	quality	of	life,	in	particular	disfiguring	changes	to	the	eyes	and	face	which	can	have	a	direct	impact	on	psychological	health	(Coulter,	Frewin,	Krassas	&	Perros,	2007).	As	the	aim	of	treating	GO/TED	is	to	improve	patients’	visual	function	as	well	as	making	them	look	and	feel	better,	it	is	important	to	assess	the	patients’	perception	of	these	markers	as	part	of	a	clinical	trial.	The	GO-QOL	questionnaire	was	developed	by	Terwee,	Gerding,	Dekker,	Prummel	&	Wiersinga	(1998)	as	a	TED	specific	quality	of	life	questionnaire	that	can	be	used	as	an	outcome	measure	for	studies	and	may	also	be	of	use	in	clinical	practice.	Marcocci	et	al	(2011)	tested	the	use	of	selenium	in	mild	GO	and	used	the	GO-QOL	to	evaluate	quality	of	life	outcomes.	They	showed	a	correlation	that	indicated	that	as	participants’	improved	with	selenium	treatment	their	quality	of	life	also	improved,	as	measured	by	the	GO-QOL.	However,	to	our	knowledge,	the	CIRTED	trial	would	be	the	first	time	that	the	measure	has	been	used	in	a	population	with	moderately	active	TED	being	treated	in	a	secondary	care	setting.		The	aim	of	this	three	stage	project	was	to	validate	the	use	of	the	English	version	of	GO-QOL	 in	an	UK	population	with	TED.	The	GO-QOL	has	been	 translated	 from	Dutch;	 the	Dutch	version	has	previously	been	validated	in	the	Netherlands	(Terwee	et	al,	1999).	In	the	first	stage	of	the	work,	the	internal	validity	and	test-retest	study,	the	objective	was	








Clinician	ratings	of	disease	severity	and	activity	were	also	included.	The	Binary	Composite	Outcome	Score	(BCCOM)	a system of major and minor criteria used in previous 











-	clinician-rating	-	binary	composite	outcome	score	with a positive result 
(improvement with no concomitant deterioration) versus no 

















1	 -2	weeks	Enrolment		 GO-QOL,	WHO-QOL,	VAS,		demographic	data	 157	
2	 0	weeks	Randomization		 GO-QOL	 133	




























Visual	Function	subscale	VF1	Cycling	 87	 1	 3	 2.43	 0.80	VF2	Driving	 103	 1	 3	 2.19	 0.81	VF3	Walking	indoors	 139	 1	 3	 2.71	 0.54	VF4	Walking	outdoors	 141	 1	 3	 2.49	 0.64	VF5	Reading	 140	 1	 3	 2.01	 0.70	VF6	Watching	TV	 141	 1	 3	 2.12	 0.68	VF7	Hobbies	 122	 1	 3	 2.29	 0.77	VF8	Interference	with	daily	life	 141	 1	 3	 2.10	 0.77	
Appearance	subscale	











Visual	Function	subscale	VF1	Cycling	 75	 1	 3	 2.59	 0.68	VF2	Driving	 93	 1	 3	 2.38	 0.75	VF3	Walking	indoors	 125	 1	 3	 2.72	 0.47	VF4	Walking	outdoors	 127	 1	 3	 2.61	 0.61	VF5	Reading	 127	 1	 3	 2.23	 0.69	VF6	Watching	TV	 126	 1	 3	 2.36	 0.66	VF7	Hobbies	 110	 1	 3	 2.47	 0.69	VF8	Interference	with	daily	life	 127	 1	 3	 2.28	 0.73	



























Go-QoL	subscales:	Visual	Function	 65.94	±28.49	 72.49	±26.64	 76.11	±24.73	 11.034	p<0.001	 0.114	Medium	Appearance	 54.1		±26.54	 58.81	±27.25	 60.84	±28.75	 13.061	p<0.002	 0.069	Medium	





	 T1	 T2	 VAS	Noticeability	 VAS	Severity	
Week	12	GO-QOL	subscales:	Visual	Function	-0.413**	 0.015	 					-0.108	 	-0.117	Appearance	 -0.409**	-0.580**	 -0.587**	 -0.552**	
Week	12	WHOQOL-Bref	subscales:	Psychological	 -0.284**	-0.475**	 -0.399**	 	-0.127	Physical	 -0.451**	-0.612**	 -0.383**	 -0.466**	Social	 	-0.193	 -0.307**							-0.167	 -0.262*	Environment	 -0.295**	-0.508**	 -0.346**	 -0.253**		 	 	 	 	
Week	48	GO-QOL	subscales:	Visual	Function	 -0.017	 -0.162	 0.014	 -0.046	Appearance	 -0.389**	-0.574**	 -0.723**	 -0.678**	
Week	48	WHOQOL-Bref	subscales:	Psychological	 0.19	 0.017	 -0.037	 0.148	Physical	 0.149	 -0.005	 -0.106	 -0.024	Social	 0.158	 0.083	 -0.151	 0.089	





Variable	 Study	time	point	48	weeks			 -1	deteriorated	 +1	improved	N	 58	 36	Age	 50.31±10.72	 48.72±10.53	Sex	(male/female)	 12/46	 12/24	




GO-QOL	 BCCOM	 Mean±sd	 p	Sig.	(2-tailed)	Visual	Function	 +1	(improved)		 83.06±21.06	 0.006		 -1(deteriorated)	 67.86±26.46	Appearance	 +1	(improved)		 64.89±28.33	 0.152	
	 -1	(deteriorate)	 55.89±28.26	
WHOQoL	 	 	 	Psychological	 +1	(improved)		 51.73±22.32	 0.138	
	 -1(deteriorated)	 59.61±19.29	Physical	 +1	(improved)		 58.08±22.27	 0.537	




GO-QOL	 VAS	noticeability	 Mean±sd	 p	Sig.	(2-tailed)	Visual	Function	 <5.0	(improved,	n=45)		 84.63±20.72	 0.001		 >5.1(noticeable,	n=54)	 66.37±26.36	Appearance	 <5.0	(improved,	n=45)		 79.86±18.17	 0.001	
	 >5.1(noticeable,	n=55)	 45.23±25.11	
	 VAS	severity	 	 	Visual	Function	 <5.0	(improved,	n=53)		 84.00±20.46	 0.001	






a	recent	study	testing	Teprotumumab	for	thyroid-associated	ophthalmology	(Smith	et	al,	2017).	While	both	subscales	of	the	GO-QOL	showed	significant	change	over	time	in	Smith	et	al’s	study,	the	Visual	Function	subscale	was	the	one	with	the	greatest	change	over	time,	as	also	suggested	in	our	data.		The	analysis	with	the	transitional	variables	is	more	equivocal.	The	hypothesized	changes	in	clinical	characteristics	were	generally	associated	with	significant	correlations	for	both	quality	of	life	measures	with	the	transitional	variables	at	the	12	week	time	point.	By	the	48	week	time	point	only	the	GO-QOL	appearance	subscale	recorded	significant	correlations	with	the	T1	(my	eye	condition	causes	me	pain	and	discomfort)	and	T2	(my	eye	condition	limits	my	ability	to	do	the	things	I	want	to	do).	Given	the	focus	of	the	T1	and	T2	variables	on	what	might	be	considered	to	be	issues	more	associated	with	visual	function,	it	is	curious	that	the	observed	correlations	are	with	the	appearance	subscale.	The	Visual	Analogue	Scales	in	the	study	are	more	focused	on	what	might	be	considered	appearance	issues	–	the	perceived	noticeability	and	severity	of	the	TED.	It	is	probably	no	surprise	that	these	were	significantly	correlated	with	the	appearance	subscale	of	the	GO-QOL	at	both	the	12	week	and	48	week	study	time	points.			The	GO-QOL	has	also	demonstrated	discriminant	validity,	with	the	visual	function	subscale	being	able	to	detect	changes	in	groups	identified	by	clinicians	(using	BCCOM	ratings	of	improvement	or	deterioration),	while	both	subscales	could	detect	group	differences	when	based	on	participants’	ratings	of	TED	noticeability	and	severity.	It	has	been	suggested	that	patients with TED overrated the extent to which their appearance was 
affected, while endocrinologists underrated it (Terwee et al, 2003). Of course, the measures 
employed do not necessarily take into account the reference point, i.e. patients are possibly 
comparing themselves prior to TED, or with other people who do not have the disease at all, 
whereas clinicians could be comparing across individuals who have TED. Without 
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